Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …

The treatment of acute ischemic stroke continues to advance. The mainstay of treatment
remains intravenous thrombolysis with alteplase. Recent studies demonstrated that later …

Background Whether thrombectomy alone is equally as effective as intravenous alteplase
plus thrombectomy remains controversial. We aimed to determine whether thrombectomy …

Background The benefit of combined treatment with intravenous thrombolysis before
endovascular thrombectomy in patients with acute ischaemic stroke caused by large vessel …

Background Intravenous thrombolysis is recommended before endovascular treatment, but
its value has been questioned in patients who are admitted directly to centres capable of …

Importance The benefit of intravenous thrombolysis (IVT) for acute ischemic stroke declines
with longer time from symptom onset, but it is not known whether a similar time dependency …

Background Aspirin and unfractionated heparin are often used during endovascular stroke
treatment to improve reperfusion and outcomes. However, the effects and risks of anti …

Abstract During the last 5–7 years, tremendous progress was achieved in the reperfusion
treatment of acute ischaemic stroke during its first few hours from symptom onset. This …

Six randomized controlled clinical trials have assessed whether mechanical thrombectomy
(MT) alone is non-inferior to intravenous thrombolysis (IVT) plus MT within 4.5 hours of …

Importance International guidelines recommend avoiding intravenous thrombolysis (IVT) in
patients with ischemic stroke who have a recent intake of a direct oral anticoagulant (DOAC) …